Fresenius Medical Care AG (ETR:FME)
Germany · Delayed Price · Currency is EUR 37.34
+0.14 (0.38%)
May 8, 2026, 5:35 PM CET
Fresenius Medical Care AG Income Statement
Financials in millions EUR. Fiscal year is January - December.
Millions EUR. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 19,358 | 19,628 | 19,336 | 19,454 | 19,398 | 17,619 | |
Revenue Growth (YoY) | -0.69% | 1.51% | -0.60% | 0.29% | 10.10% | -1.35% |
Cost of Revenue | 14,334 | 14,599 | 14,579 | 14,529 | 14,504 | 12,846 |
Gross Profit | 5,024 | 5,029 | 4,757 | 4,925 | 4,894 | 4,773 |
Selling, General & Admin | 3,031 | 3,033 | 3,143 | 3,196 | 3,170 | 2,773 |
Research & Development | 152.8 | 157.98 | 183.49 | 231.97 | 228.62 | 220.78 |
Other Operating Expenses | -23.04 | -31.65 | -109.03 | -26.86 | -43.25 | -124.41 |
Operating Expenses | 3,161 | 3,159 | 3,217 | 3,401 | 3,356 | 2,869 |
Operating Income | 1,864 | 1,870 | 1,539 | 1,524 | 1,538 | 1,904 |
Interest Expense | -381.99 | -384.41 | -407.04 | -424.64 | -360.14 | -353.6 |
Interest & Investment Income | 69.25 | 69.61 | 71.58 | 88.22 | 67.66 | 73.17 |
Earnings From Equity Investments | 174.86 | 181.37 | 134.88 | 121.79 | 66.56 | 92.18 |
Currency Exchange Gain (Loss) | -40.3 | -43.79 | -23.06 | -35.5 | -36.83 | -9.9 |
EBT Excluding Unusual Items | 1,686 | 1,693 | 1,316 | 1,273 | 1,275 | 1,706 |
Merger & Restructuring Charges | -214.93 | -104.37 | -317.48 | -259.92 | -147.95 | -37.55 |
Gain (Loss) on Sale of Investments | -15.79 | -77.04 | 44.03 | 14.67 | 44.85 | -87.63 |
Gain (Loss) on Sale of Assets | 14.3 | 0.99 | 14.66 | 4.84 | 47.17 | -8.63 |
Pretax Income | 1,469 | 1,512 | 1,057 | 1,033 | 1,219 | 1,572 |
Income Tax Expense | 302.68 | 320.97 | 316.06 | 300.56 | 324.95 | 352.83 |
Earnings From Continuing Operations | 1,166 | 1,191 | 740.87 | 732.46 | 894.33 | 1,219 |
Minority Interest in Earnings | -221.75 | -212.9 | -202.96 | -233.46 | -220.92 | -249.72 |
Net Income | 944.68 | 978.37 | 537.91 | 499 | 673.41 | 969.31 |
Net Income to Common | 944.68 | 978.37 | 537.91 | 499 | 673.41 | 969.31 |
Net Income Growth | 52.82% | 81.88% | 7.80% | -25.90% | -30.53% | -16.75% |
Shares Outstanding (Basic) | 287 | 291 | 293 | 293 | 293 | 293 |
Shares Outstanding (Diluted) | 287 | 291 | 293 | 293 | 293 | 293 |
Shares Change (YoY) | -2.31% | -0.76% | - | 0.06% | 0.06% | -0.41% |
EPS (Basic) | 3.30 | 3.36 | 1.83 | 1.70 | 2.30 | 3.31 |
EPS (Diluted) | 3.29 | 3.36 | 1.83 | 1.70 | 2.30 | 3.31 |
EPS Growth | 56.34% | 83.60% | 7.65% | -25.97% | -30.60% | -16.44% |
Free Cash Flow | 1,785 | 1,766 | 1,687 | 1,944 | 1,443 | 1,635 |
Free Cash Flow Per Share | 6.23 | 6.06 | 5.75 | 6.63 | 4.92 | 5.58 |
Dividend Per Share | 1.490 | 1.490 | 1.440 | 1.190 | 1.120 | 1.350 |
Dividend Growth | 3.47% | 3.47% | 21.01% | 6.25% | -17.04% | 0.75% |
Gross Margin | 25.96% | 25.62% | 24.60% | 25.32% | 25.23% | 27.09% |
Operating Margin | 9.63% | 9.53% | 7.96% | 7.83% | 7.93% | 10.81% |
Profit Margin | 4.88% | 4.98% | 2.78% | 2.56% | 3.47% | 5.50% |
Free Cash Flow Margin | 9.22% | 9.00% | 8.72% | 9.99% | 7.44% | 9.28% |
EBITDA | 2,592 | 2,622 | 2,347 | 2,436 | 2,512 | 2,799 |
EBITDA Margin | 13.39% | 13.36% | 12.14% | 12.52% | 12.95% | 15.88% |
D&A For EBITDA | 728.5 | 752.56 | 807.31 | 912.07 | 973.66 | 894.89 |
EBIT | 1,864 | 1,870 | 1,539 | 1,524 | 1,538 | 1,904 |
EBIT Margin | 9.63% | 9.53% | 7.96% | 7.83% | 7.93% | 10.81% |
Effective Tax Rate | 20.60% | 21.22% | 29.90% | 29.09% | 26.65% | 22.45% |
Revenue as Reported | 19,358 | 19,628 | 19,336 | 19,454 | 19,398 | 17,619 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.